Pyxis Oncology, Inc.
HealthcareNASDAQ:PYXS · NASDAQ Global Select
+$0.09 today
Vol 0.44M · Avg 0.50M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$79.6M -3.0% | -$77.3M -4.8% | -$73.8M +38.9% | -$120.7M -58.9% | -$76.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $4.5M +51.3% | $3.0M +54.7% | $1.9M +171.8% | $709.0K +9.6% | $647.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $6.3M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $11.8M -8.8% | $12.9M -23.6% | $16.9M +7.5% | $15.8M +144.7% | $6.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $1.9M +116.4% | -$11.8M -1.4% | -$11.7M -359.1% | $4.5M -32.6% | $6.7M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $6.0M +402.2% | $1.2M +134.2% | -$3.5M +57.9% | -$8.3M -279.4% | $4.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$4.1M +68.6% | -$13.0M -59.7% | -$8.2M -163.6% | $12.8M +531.0% | $2.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$2.1M -113.7% | $15.6M +476.8% | -$4.1M -139.7% | $10.4M -49.5% | $20.6M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$63.5M -10.1% | -$57.7M +18.4% | -$70.7M +20.8% | -$89.3M -152.9% | -$35.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$9.0K +96.2% | -$237.0K +96.5% | -$6.7M -5.1% | -$6.4M -1085.0% | -$540.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 -100.0% | $6.7M | $0 +100.0% | -$50.0K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$107.0M +33.2% | -$160.1M +18.7% | -$196.8M | $0 +100.0% | -$50.0K | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $165.9M -1.6% | $168.5M +83.1% | $92.0M | $0 -100.0% | $50.0K | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 +100.0% | -$50 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $58.9M +621.7% | $8.2M +107.8% | -$104.8M -1538.5% | -$6.4M -984.6% | -$590.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $742.0K -98.7% | $59.0M +864.5% | $6.1M | $0 -100.0% | $152.3M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$148.0K -152.9% | $280.0K +245.1% | -$193.0K -205.5% | $183.0K +9.6% | $167.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $594.0K -99.0% | $59.3M +900.6% | $5.9M +3139.9% | $183.0K -99.9% | $304.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$4.1M -141.3% | $9.8M +105.8% | -$169.6M -77.5% | -$95.6M -135.6% | $268.1M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$63.5M -9.7% | -$57.9M +25.2% | -$77.4M +19.1% | -$95.7M -166.9% | -$35.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Zura Bio Limited
NASDAQ:ZURA
$240.58M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
SEC Filings
Recent regulatory filings
No filings found.
Does PYXS generate free cash flow?
Pyxis Oncology, Inc. (PYXS) generated -$63,511,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does PYXS produce?
Operating cash flow was -$63,502,000.00, before capital expenditures of $9,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.